{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T08:07:27Z","timestamp":1780301247517,"version":"3.54.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100007675","name":"International Center for Genetic Engineering and Biotechnology","doi-asserted-by":"publisher","award":["CRP\/MYS21-04_EC"],"award-info":[{"award-number":["CRP\/MYS21-04_EC"]}],"id":[{"id":"10.13039\/100007675","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007675","name":"International Center for Genetic Engineering and Biotechnology","doi-asserted-by":"publisher","award":["CRP\/MYS21-04_EC"],"award-info":[{"award-number":["CRP\/MYS21-04_EC"]}],"id":[{"id":"10.13039\/100007675","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007675","name":"International Center for Genetic Engineering and Biotechnology","doi-asserted-by":"publisher","award":["CRP\/MYS21-04_EC"],"award-info":[{"award-number":["CRP\/MYS21-04_EC"]}],"id":[{"id":"10.13039\/100007675","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Higher Education Malaysia under the Fundamental Research Grant Scheme","award":["FRGS\/1\/2022\/STG01\/USM\/03\/2"],"award-info":[{"award-number":["FRGS\/1\/2022\/STG01\/USM\/03\/2"]}]},{"name":"Ministry of Higher Education Malaysia under the Fundamental Research Grant Scheme","award":["FRGS\/1\/2022\/STG01\/USM\/03\/2"],"award-info":[{"award-number":["FRGS\/1\/2022\/STG01\/USM\/03\/2"]}]},{"name":"Ministry of Higher Education Malaysia under the Fundamental Research Grant Scheme","award":["FRGS\/1\/2022\/STG01\/USM\/03\/2"],"award-info":[{"award-number":["FRGS\/1\/2022\/STG01\/USM\/03\/2"]}]},{"DOI":"10.13039\/501100004595","name":"Universiti Sains Malaysia","doi-asserted-by":"crossref","award":["R501-LR-RND002-0000001810-0000"],"award-info":[{"award-number":["R501-LR-RND002-0000001810-0000"]}],"id":[{"id":"10.13039\/501100004595","id-type":"DOI","asserted-by":"crossref"}]},{"name":"ed by the Universiti Sains Malaysia","award":["R501-LR-RND002-0000001810-0000"],"award-info":[{"award-number":["R501-LR-RND002-0000001810-0000"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03294-7","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T07:57:16Z","timestamp":1777103836000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Rho\/PAK signaling: a key driver of anthracycline and taxane resistance in breast cancer"],"prefix":"10.1007","volume":"43","author":[{"given":"Nurul Syafawani","family":"Fizal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nik Yasmin Umaira","family":"Hasnizan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien Fung","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saw Keat","family":"Chuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha Fatima","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Masara Ahmad","family":"Mokhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"issue":"16","key":"3294_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14163876","volume":"14","author":"F Derouane","year":"2022","unstructured":"Derouane F, Marcke C, Berli\u00e8re M, Gerday A, Fellah L, Leconte I, et al. Predictive biomarkers of response to neoadjuvant chemotherapy in breast cancer: current and future perspectives for precision medicine [Review of predictive biomarkers of response to neoadjuvant chemotherapy in breast cancer: current and future perspectives for precision medicine]. Cancers. 2022;14(16):3876. https:\/\/doi.org\/10.3390\/cancers14163876.","journal-title":"Cancers"},{"issue":"21","key":"3294_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15215288","volume":"15","author":"BB ELSayed","year":"2023","unstructured":"ELSayed BB, Alksas A, Shehata M, Mahmoud A, Zaky M, Alghandour R, et al. Exploring neoadjuvant chemotherapy, predictive models, radiomic, and pathological markers in breast cancer: a comprehensive review [Review of exploring neoadjuvant chemotherapy, predictive models, radiomic, and pathological markers in breast cancer: a comprehensive review]. Cancers. 2023;15(21):5288. https:\/\/doi.org\/10.3390\/cancers15215288.","journal-title":"Cancers"},{"issue":"7","key":"3294_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11070972","volume":"11","author":"D Ku\u010diauskas","year":"2019","unstructured":"Ku\u010diauskas D, Drei\u017e\u0117 N, Ger M, Kaupinis A, \u017demaitis K, Stankevi\u010dius V, et al. Proteomic analysis of breast cancer resistance to the anticancer drug RH1 reveals the importance of cancer stem cells. Cancers. 2019;11(7):972. https:\/\/doi.org\/10.3390\/cancers11070972.","journal-title":"Cancers"},{"issue":"3","key":"3294_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031665","volume":"23","author":"P Ferrari","year":"2022","unstructured":"Ferrari P, Scatena C, Ghilli M, Bargagna I, Lorenzini G, Nicolini A, et al. Molecular mechanisms, biomarkers and emerging therapies for chemotherapy resistant TNBC [Review of Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC]. Int J Mol Sci. 2022;23(3):1665. https:\/\/doi.org\/10.3390\/ijms23031665.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"3294_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061404","volume":"12","author":"JS Lee","year":"2020","unstructured":"Lee JS, Yost SE, Yuan Y. Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges [Review of Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges]. Cancers. 2020;12(6):1404. https:\/\/doi.org\/10.3390\/cancers12061404.","journal-title":"Cancers"},{"key":"3294_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-84785-3","author":"T Ma","year":"2025","unstructured":"Ma T, Hao X, Chen H, Zheng M, Chen X, Cai S-L, et al. Predictive markers of rapid disease progression and chemotherapy resistance in triple-negative breast cancer patients following postoperative adjuvant therapy. Sci Rep. 2025. https:\/\/doi.org\/10.1038\/s41598-024-84785-3.","journal-title":"Sci Rep"},{"key":"3294_CR7","doi-asserted-by":"publisher","unstructured":"Yin L, Duan J-J, Bian X-W, Yu S. Triple-negative breast cancer molecular subtyping and treatment progress [Review of Triple-negative breast cancer molecular subtyping and treatment progress]. Breast Cancer Res. 2020;22(1).\u00a0BioMed Central.\u00a0https:\/\/doi.org\/10.1186\/s13058-020-01296-5.\u00a0","DOI":"10.1186\/s13058-020-01296-5"},{"issue":"3","key":"3294_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032969","volume":"24","author":"N Ende","year":"2023","unstructured":"Ende N, Nguyen AH, Jager A, Kok M, Debets R, Deurzen C. Triple-negative breast cancer and predictive markers of response to neoadjuvant chemotherapy: a systematic review [Review of triple-negative breast cancer and predictive markers of response to neoadjuvant chemotherapy: a systematic review]. Int J Mol Sci. 2023;24(3):2969. https:\/\/doi.org\/10.3390\/ijms24032969.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"3294_CR9","doi-asserted-by":"publisher","DOI":"10.21037\/atm-21-698","volume":"9","author":"H Hu","year":"2021","unstructured":"Hu H, Zhu J, Zhong Y, Geng R, Ji Y, Guan Q, et al. PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K\/AKT\/mTOR signaling pathway. Ann Transl Med. 2021;9(5):410. https:\/\/doi.org\/10.21037\/atm-21-698.","journal-title":"Ann Transl Med"},{"key":"3294_CR10","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431x2021e11857","author":"MC Kneubil","year":"2022","unstructured":"Kneubil MC, Goulart KOB, Brollo J, Coelho GP, Mandelli J, Orlandin BC, et al. Predictive value of DNA repair gene expression for response to neoadjuvant chemotherapy in breast cancer. Braz J Med Biol Res. 2022. https:\/\/doi.org\/10.1590\/1414-431x2021e11857.","journal-title":"Braz J Med Biol Res"},{"key":"3294_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbior.2020.100758","volume":"78","author":"LS Steelman","year":"2020","unstructured":"Steelman LS, Chappell WH, Akula SM, Abrams SL, Cocco L, Manzoli L, et al. Therapeutic resistance in breast cancer cells can result from deregulated EGFR signaling [Review of Therapeutic resistance in breast cancer cells can result from deregulated EGFR signaling]. Adv Biol Regul. 2020;78:100758. https:\/\/doi.org\/10.1016\/j.jbior.2020.100758.","journal-title":"Adv Biol Regul"},{"issue":"19","key":"3294_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194571","volume":"14","author":"F Pavese","year":"2022","unstructured":"Pavese F, Capoluongo E, Muratore M, Minucci A, Santonocito C, Fuso P, et al. BRCA mutation status in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: a pivotal role for treatment decision-making. Cancers. 2022;14(19):4571. https:\/\/doi.org\/10.3390\/cancers14194571.","journal-title":"Cancers"},{"issue":"1","key":"3294_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24010207","volume":"24","author":"\u041c\u041c \u0426\u044b\u0433\u0430\u043d\u043e\u0432","year":"2022","unstructured":"\u0426\u044b\u0433\u0430\u043d\u043e\u0432 \u041c\u041c, \u0418\u0431\u0440\u0430\u0433\u0438\u043c\u043e\u0432\u0430 \u041c\u041a, Garbukov \u0415Y, Bragina O, Karchevskaya AA, Usynin EA, et al. Determination of BRCAness phenotype in breast tumors for the appointment of neoadjuvant chemotherapy based on platinum and taxanes. Int J Mol Sci. 2022;24(1):207. https:\/\/doi.org\/10.3390\/ijms24010207.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"3294_CR14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.20892\/j.issn.2095-3941.2019.0465","volume":"17","author":"L Cao","year":"2020","unstructured":"Cao L, Niu Y. Triple negative breast cancer: special histological types and emerging therapeutic methods [Review of Triple negative breast cancer: special histological types and emerging therapeutic methods]. Cancer Biology Med. 2020;17(2):293. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2019.0465. Chinese Anti-Cancer Association.","journal-title":"Cancer Biology Med"},{"key":"3294_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-65508-0","author":"A Hakeem","year":"2024","unstructured":"Hakeem A, El-Kersh DM, Hammam O, Elhosseiny A, Zaki AR, Kamel K, et al. Piperine enhances doxorubicin sensitivity in triple-negative breast cancer by targeting the PI3K\/Akt\/mTOR pathway and cancer stem cells. Sci Rep. 2024. https:\/\/doi.org\/10.1038\/s41598-024-65508-0.","journal-title":"Sci Rep"},{"issue":"16","key":"3294_CR16","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.3390\/cancers13163949","volume":"13","author":"F Rascio","year":"2021","unstructured":"Rascio F, Spadaccino F, Rocchetti MT, Castellano G, Stallone G, Netti GS, et al. The pathogenic role of PI3K\/AKT pathway in cancer onset and drug resistance: an updated review [Review of The Pathogenic Role of PI3K\/AKT Pathway in Cancer Onset and Drug Resistance: An Updated Review]. Cancers. 2021;13(16):3949. https:\/\/doi.org\/10.3390\/cancers13163949.","journal-title":"Cancers"},{"issue":"2","key":"3294_CR17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3390\/cancers17020234","volume":"17","author":"VK Panda","year":"2025","unstructured":"Panda VK, Mishra B, Mahapatra S, Swain B, Malhotra D, Saha S, et al. Molecular insights on signaling cascades in breast cancer: a comprehensive review [Review of Molecular Insights on Signaling Cascades in Breast Cancer: A Comprehensive Review]. Cancers. 2025;17(2):234. https:\/\/doi.org\/10.3390\/cancers17020234.","journal-title":"Cancers"},{"issue":"13","key":"3294_CR18","doi-asserted-by":"publisher","first-page":"11061","DOI":"10.18632\/oncotarget.3568","volume":"6","author":"H-E Tzeng","year":"2015","unstructured":"Tzeng H-E, Yang L, Chen K, Wang Y, Liu Y-R, Pan S, Gaur S, Hu S, Yen Y. The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor. Oncotarget. 2015;6(13):11061. https:\/\/doi.org\/10.18632\/oncotarget.3568.","journal-title":"Oncotarget"},{"key":"3294_CR19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.phrs.2015.09.019","volume":"102","author":"L Tao","year":"2015","unstructured":"Tao L, Zhu F, Xu F, Chen Z, Jiang Y, Chen Y. Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs [Review of Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs]. Pharmacol Res. 2015;102:123. https:\/\/doi.org\/10.1016\/j.phrs.2015.09.019.","journal-title":"Pharmacol Res"},{"issue":"6","key":"3294_CR20","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3892\/ijo.2020.5135","volume":"57","author":"K Won","year":"2020","unstructured":"Won K, Spruck C. Triple\u2011negative breast cancer therapy: current and future perspectives (Review) [Review of Triple\u2011negative breast cancer therapy: Current and future perspectives (Review)]. Int J Oncol. 2020;57(6):1245. https:\/\/doi.org\/10.3892\/ijo.2020.5135.","journal-title":"Int J Oncol"},{"key":"3294_CR21","doi-asserted-by":"publisher","DOI":"10.7554\/elife.59696","author":"AE Yesilkanal","year":"2021","unstructured":"Yesilkanal AE, Yang D, Valdespino A, Tiwari P, Sabino AU, Nguyen LC, et al. Limited inhibition of multiple nodes in a driver network blocks metastasis. Elife. 2021. https:\/\/doi.org\/10.7554\/elife.59696.","journal-title":"Elife"},{"issue":"12","key":"3294_CR22","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1515\/nanoph-2021-0142","volume":"10","author":"T Saha","year":"2021","unstructured":"Saha T, Mondal J, Khiste S, Lusic H, Hu Z, Jayabalan R, Hodgetts KJ, Jang H, Sengupta S, Lee SE, Park Y, Lee LP, Goldman A. Nanotherapeutic approaches to overcome distinct drug resistance barriers in models of breast cancer. Nanophotonics. 2021;10(12):3063. https:\/\/doi.org\/10.1515\/nanoph-2021-0142.","journal-title":"Nanophotonics"},{"issue":"5","key":"3294_CR23","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1080\/14728222.2017.1306055","volume":"21","author":"J Yang","year":"2017","unstructured":"Yang J, Farren MR, Ahn DH, Bekaii-Saab T, Lesinski GB. Signaling pathways as therapeutic targets in biliary tract cancer [Review of Signaling pathways as therapeutic targets in biliary tract cancer]. Expert Opin Ther Targets. 2017;21(5):485. https:\/\/doi.org\/10.1080\/14728222.2017.1306055.","journal-title":"Expert Opin Ther Targets"},{"issue":"8","key":"3294_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12081801","volume":"12","author":"M Koirala","year":"2024","unstructured":"Koirala M, DiPaola M. Overcoming cancer resistance: strategies and modalities for effective treatment [Review of Overcoming Cancer Resistance: Strategies and Modalities for Effective Treatment]. Biomedicines. 2024;12(8):1801. https:\/\/doi.org\/10.3390\/biomedicines12081801.","journal-title":"Biomedicines"},{"key":"3294_CR25","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s12282-024-01572-8","volume":"31","author":"A Shimomura","year":"2024","unstructured":"Shimomura A, Sagara Y, Koto R, Fujiwara M, Kanemura Y, Kitagawa H, Saji S. Real-world data of HER2-negative early breast cancer patients treated with anthracycline and\/or taxane regimens in Japan. Breast Cancer. 2024;31:581\u201392. https:\/\/doi.org\/10.1007\/s12282-024-01572-8.","journal-title":"Breast Cancer"},{"key":"3294_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5890-z","volume":"19","author":"M Laible","year":"2019","unstructured":"Laible M, Hartmann K, G\u00fcrtler C, Anzeneder T, Wirtz R, Weber S, et al. Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy. BMC Cancer. 2019;19:694. https:\/\/doi.org\/10.1186\/s12885-019-5890-z.","journal-title":"BMC Cancer"},{"issue":"3","key":"3294_CR27","doi-asserted-by":"publisher","first-page":"412","DOI":"10.5306\/wjco.v5.i3.412.","volume":"5","author":"O Yersal","year":"2014","unstructured":"Yersal O, Barutca S. Biological subtypes of breast cancer: prognostic and therapeutic implications. World J Clin Oncol. 2014;5(3):412\u201324. https:\/\/doi.org\/10.5306\/wjco.v5.i3.412.","journal-title":"World J Clin Oncol"},{"key":"3294_CR28","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.breast.2020.04.005","volume":"52","author":"NI Bouwer","year":"2020","unstructured":"Bouwer NI, Jager A, Liesting C, Kofflard MJM, Brugts JJ, Kitzen JJEM, et al. Cardiac monitoring in HER2-positive patients on trastuzumab treatment: a review and implications for clinical practice. Breast. 2020;52:33\u201344. https:\/\/doi.org\/10.1016\/j.breast.2020.04.005.","journal-title":"Breast"},{"issue":"4","key":"3294_CR29","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1053\/j.seminoncol.2020.05.006","volume":"47","author":"LN Chaudhary","year":"2020","unstructured":"Chaudhary LN. Early stage triple negative breast cancer: management and future directions. Semin Oncol. 2020;47(4):201\u20138. https:\/\/doi.org\/10.1053\/j.seminoncol.2020.05.006.","journal-title":"Semin Oncol"},{"key":"3294_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21037\/pcm-20-6","volume":"4","author":"L Maria","year":"2021","unstructured":"Maria L, Romero L, Pezo RC. A narrative review of chemotherapy in advanced triple negative breast cancer. Precision Cancer Med. 2021;4:1\u201319. https:\/\/doi.org\/10.21037\/pcm-20-6.","journal-title":"Precision Cancer Med"},{"issue":"6","key":"3294_CR31","doi-asserted-by":"publisher","first-page":"533","DOI":"10.4065\/84.6.533","volume":"84","author":"A Moreno-Aspitia","year":"2009","unstructured":"Moreno-Aspitia A, Perez EA. Treatment options for breast cancer resistant to anthracycline and taxane. Mayo Clin Proc. 2009;84(6):533\u201345. https:\/\/doi.org\/10.4065\/84.6.533.","journal-title":"Mayo Clin Proc"},{"key":"3294_CR32","doi-asserted-by":"publisher","unstructured":"Rivera E, Gomez H. Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone. Breast Cancer Res. 2010;1\u201312. https:\/\/doi.org\/10.1186\/bcr2573.","DOI":"10.1186\/bcr2573"},{"key":"3294_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112375","volume":"145","author":"JA Malik","year":"2021","unstructured":"Malik JA, Ahmed S, Jan B, Bender O, Hagbani TA, Alqarni A, et al. Drugs repurposed: An advanced step towards the treatment of breast cancer and associated challenges [Review of Drugs repurposed: An advanced step towards the treatment of breast cancer and associated challenges]. Biomed Pharmacother. 2021;145:112375. https:\/\/doi.org\/10.1016\/j.biopha.2021.112375.","journal-title":"Biomed Pharmacother"},{"key":"3294_CR34","doi-asserted-by":"publisher","unstructured":"Dhingra R, Margulets V, Kirshenbaum LA. Chapter 2 - Molecular Mechanisms Underlying Anthracycline Cardiotoxicity: Challenges in Cardio-Oncology (R. A. Gottlieb & P. K. B. T.-C.-O. Mehta, editors). Academic Press. 2017. p.25\u201334.\u00a0https:\/\/doi.org\/10.1016\/B978-0-12-803547-4.00002-1","DOI":"10.1016\/B978-0-12-803547-4.00002-1"},{"key":"3294_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/413076","volume":"2015","author":"DN Kampan","year":"2015","unstructured":"Kampan DN, Madondo M, McNally O, Quinn M, Plebanski M. Paclitaxel and its evolving role in the management of ovarian cancer. Biomed Res Int. 2015;2015:1\u201321. https:\/\/doi.org\/10.1155\/2015\/413076.","journal-title":"Biomed Res Int"},{"issue":"10","key":"3294_CR36","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1023\/a:1008208002779","volume":"8","author":"P Cont\u00e9","year":"1997","unstructured":"Cont\u00e9 P, Gennari A. Anthracyclines-paclitaxel combinations in the treatment of breast cancer [Review of Anthracyclines-paclitaxel combinations in the treatment of breast cancer]. Ann Oncol. 1997;8(10):939. https:\/\/doi.org\/10.1023\/a:1008208002779. Elsevier BV.","journal-title":"Ann Oncol"},{"key":"3294_CR37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.breast.2022.06.007","volume":"65","author":"AT Vuger","year":"2022","unstructured":"Vuger AT, Tiscoski KA, Apolinario T, Cardoso F. Anthracyclines in the treatment of early breast cancer friend or foe? [Review of Anthracyclines in the treatment of early breast cancer friend or foe?]. Breast. 2022;65:67. https:\/\/doi.org\/10.1016\/j.breast.2022.06.007.","journal-title":"Breast"},{"key":"3294_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118364","volume":"190","author":"D Haghmorad","year":"2025","unstructured":"Haghmorad D, Razavi FT, Eivazzadeh Y, Yazdanpanah E, Orooji N. Therapeutic challenges in breast cancer: navigating the impact of oxidative stress on treatment efficacy and toxicity. Biomed Pharmacother. 2025;190:118364. https:\/\/doi.org\/10.1016\/j.biopha.2025.118364.","journal-title":"Biomed Pharmacother"},{"key":"3294_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.571810","volume":"11","author":"S Zhao","year":"2020","unstructured":"Zhao S, Chen F, Yin Q, Wang D, Han W, Zhang Y. Reactive Oxygen Species Interact With NLRP3 Inflammasomes and Are Involved in the Inflammation of Sepsis: from mechanism to treatment of progression. Front Physiol. 2020;11:571810. https:\/\/doi.org\/10.3389\/fphys.2020.571810.","journal-title":"Front Physiol"},{"issue":"5","key":"3294_CR40","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/sj.clpt.6100296","volume":"83","author":"M Mimeault","year":"2008","unstructured":"Mimeault M, Hauke R, Batra SK. Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther. 2008;83(5):673\u201391. https:\/\/doi.org\/10.1038\/sj.clpt.6100296.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"3294_CR41","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/0306-3623(95)02013-6","volume":"27","author":"D Nielsen","year":"1996","unstructured":"Nielsen D, Maare C, Skovsgaard T. Cellular resistance to anthracyclines. Gen Pharmacol. 1996;27(2):251\u20135. https:\/\/doi.org\/10.1016\/0306-3623(95)02013-6.","journal-title":"Gen Pharmacol"},{"key":"3294_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1584630","author":"Q Wang","year":"2025","unstructured":"Wang Q, L i, Li L, Li Q, Qi Y, Liu K, et al. The role and therapeutic potential of glucose metabolism in multidrug resistance of cancer. Front Cell Dev Biol. 2025. https:\/\/doi.org\/10.3389\/fcell.2025.1584630.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"3294_CR43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.seminoncol.2025.152337","volume":"52","author":"BB Kuriakose","year":"2025","unstructured":"Kuriakose BB, Zwamel AH, Mutar AA, Uthirapathy S, Bishoyi AK, Naidu KS, et al. The critical role of NLRP3 in drug resistance of cancers: focus on the molecular mechanisms and possible therapeutics. Semin Oncol. 2025;52(1):27\u201340. https:\/\/doi.org\/10.1016\/j.seminoncol.2025.152337.","journal-title":"Semin Oncol"},{"key":"3294_CR44","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1021\/acs.molpharmaceut.2c00140","volume":"7","author":"S Saib","year":"2022","unstructured":"Saib S, Hodin S, Mercier C, Pau l, Bin V, Ollier E, et al. TNF-\u03b1 and IL-1\u03b2 exposure modulates the expression and functionality of P-glycoprotein in intestinal and renal barriers. Molecular Pharmaceutics Journal, 19. 2022;7:2327\u201334. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.2c00140.","journal-title":"Molecular Pharmaceutics Journal, 19"},{"issue":"3","key":"3294_CR45","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrd1984","volume":"5","author":"G Szak\u00e1cs","year":"2006","unstructured":"Szak\u00e1cs G, Paterson JK, Ludwig JA, Booth-Groves B, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5(3):219\u201334.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"3294_CR46","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1002\/med.20239","volume":"32","author":"S Nobili","year":"2012","unstructured":"Nobili S, Landini I, Mazzei T, Mini E. Overcoming tumor multidrug resistance: drugs that and evade P-glycoprotein or exploit its expression. Med Res Rev. 2012;32(6):1220\u201362.","journal-title":"Med Res Rev"},{"key":"3294_CR47","unstructured":"Shapiro AB, Ling V. Uptake and efflux of anticancer drugs by Pglycoprotein. Molecular Pharmacology.\u00a0Provides evidence that anthracycline compounds like doxorubicin are effluxed by P-gp through substrate recognition.\u00a02001;60(5):1009\u20131016."},{"key":"3294_CR48","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2020.64","author":"Z Torres-Mart\u00ednez","year":"2020","unstructured":"Torres-Mart\u00ednez Z, Delgado Y, Ferrer\u2010Acosta Y, Suarez\u2010Arroyo IJ, Joaqu\u00edn-Ovalle FM, Delinois LJ, Griebenow K. Key genes and drug delivery systems to improve the efficiency of chemotherapy. Cancer Drug Resist. 2020. https:\/\/doi.org\/10.20517\/cdr.2020.64.","journal-title":"Cancer Drug Resist"},{"issue":"1","key":"3294_CR49","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3816\/cbc.2006.n.013","volume":"7","author":"CT Dang","year":"2006","unstructured":"Dang CT, Hudis CA, Elsevier BV. Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg [Review of Adjuvant Taxanes in the Treatment of Breast Cancer: No Longer at the Tip of the Iceberg]. Clin Breast Cancer. 2006;7(1):51. https:\/\/doi.org\/10.3816\/cbc.2006.n.013.","journal-title":"Clin Breast Cancer"},{"key":"3294_CR50","doi-asserted-by":"publisher","unstructured":"L\u00f3pez-Tarruella S, Mart\u00edn M. Recent advances in systemic therapy. Advances in adjuvant systemic chemotherapy of early breast cancer [Review of Recent advances in systemic therapy. Advances in adjuvant systemic chemotherapy of early breast cancer]. Breast Cancer Research.2009;11(2). BioMed Central. https:\/\/doi.org\/10.1186\/bcr2226","DOI":"10.1186\/bcr2226"},{"key":"3294_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01302-1","author":"SU Khan","year":"2024","unstructured":"Khan SU, Fatima K, Aisha S, Malik F. Unveiling the mechanisms and challenges of cancer drug resistance. Cell Commun Signal. 2024. https:\/\/doi.org\/10.1186\/s12964-023-01302-1.","journal-title":"Cell Commun Signal"},{"issue":"3","key":"3294_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100461","volume":"7","author":"V Guarneri","year":"2022","unstructured":"Guarneri V, Azambuja E. Anthracyclines in the treatment of patients with early breast cancer. ESMO Open. 2022;7(3):100461. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100461.","journal-title":"ESMO Open"},{"issue":"11","key":"3294_CR53","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.18632\/oncotarget.26632","volume":"10","author":"P Ntellas","year":"2019","unstructured":"Ntellas P, Spathas N, Agelaki S, \u0396\u03b9\u03bd\u03c4\u03b6\u03b1\u03c1\u03ac\u03c2 \u0397, Saloustros E. Taxane & cyclophosphamide vs anthracycline & taxane-based chemotherapy as adjuvant treatment for breast cancer: a pooled analysis of randomized controlled trials by the Hellenic Academy of Oncology. Oncotarget. 2019;10(11):1209. https:\/\/doi.org\/10.18632\/oncotarget.26632.","journal-title":"Oncotarget"},{"key":"3294_CR54","doi-asserted-by":"publisher","unstructured":"Anampa J, Makower D, Sparano JA. Progress in adjuvant chemotherapy for breast cancer: an overview [Review of Progress in adjuvant chemotherapy for breast cancer: an overview]. BMC Med.\u00a0BioMed Central. 2015;13(1). https:\/\/doi.org\/10.1186\/s12916-015-0439-8.\u00a0","DOI":"10.1186\/s12916-015-0439-8"},{"issue":"9814","key":"3294_CR55","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/s0140-6736(11)61625-5","volume":"379","author":"R Peto","year":"2012","unstructured":"Peto R, Davies C, Godwin J, Gray RJ, Pan H, Clarke M, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials [Review of Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials]. Lancet. 2012;379(9814):432. https:\/\/doi.org\/10.1016\/s0140-6736(11)61625-5.","journal-title":"Lancet"},{"issue":"10384","key":"3294_CR56","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/s0140-6736(23)00285-4","volume":"401","author":"J Braybrooke","year":"2023","unstructured":"Braybrooke J, Bradley R, Gray R, Hills RK, Pan H, Pet\u0151 R, Dodwell D, McGale P, Taylor C, Aihara T, Anderson S, Blum JL, Cardoso F, Chen X, Crown J, Ejlertsen B, Friedl TWP, Harbeck N, Janni W, van Tinteren H. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials [Review of Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials]. Lancet. 2023;401(10384):1277. https:\/\/doi.org\/10.1016\/s0140-6736(23)00285-4. Elsevier BV.","journal-title":"Lancet"},{"issue":"6","key":"3294_CR57","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/annonc\/mdu007","volume":"25","author":"J Bines","year":"2014","unstructured":"Bines J, Earl H, Buzaid AC, Saad ED. Anthracyclines and taxanes in the neo\/adjuvant treatment of breast cancer: does the sequence matter? [Review of Anthracyclines and taxanes in the neo\/adjuvant treatment of breast cancer: does the sequence matter?]. Ann Oncol. 2014;25(6):1079. https:\/\/doi.org\/10.1093\/annonc\/mdu007. Elsevier BV.","journal-title":"Ann Oncol"},{"key":"3294_CR58","doi-asserted-by":"publisher","unstructured":"Ong CC et al. Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proceedings of the National Academy of Sciences USA. 2011;108:7177\u20137182. https:\/\/doi.org\/10.1073\/pnas.1103353108","DOI":"10.1073\/pnas.1103353108"},{"key":"3294_CR59","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.gene.2016.12.014","volume":"605","author":"R Kumar","year":"2017","unstructured":"Kumar R, Sanawar R, Li X, Li F. Structure, biochemistry, and biology of PAK kinases. Gene. 2017;605:20\u201331. https:\/\/doi.org\/10.1016\/j.gene.2016.12.014.","journal-title":"Gene"},{"issue":"28","key":"3294_CR60","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1038\/onc.2009.119","volume":"28","author":"PR Molli","year":"2009","unstructured":"Molli PR, Li DQ, Murray BW, Rayala SK, Kumar R. PAK signaling in oncogenesis. Oncogene. 2009;28(28):2545\u201355. https:\/\/doi.org\/10.1038\/onc.2009.119.","journal-title":"Oncogene"},{"key":"3294_CR61","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrc3645","volume":"14","author":"M Radu","year":"2014","unstructured":"Radu M, Semenova G, Kosoff R, Chernoff J. Pak signalling during the development and progression of cancer. Nat Rev Cancer. 2014;14:13\u201325. https:\/\/doi.org\/10.1038\/nrc3645.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"3294_CR62","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/s0092-8674(00)80405-5","volume":"91","author":"SR Datta","year":"1997","unstructured":"Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91(2):231\u201341. https:\/\/doi.org\/10.1016\/s0092-8674(00)80405-5.","journal-title":"Cell"},{"key":"3294_CR63","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","volume":"169","author":"BD Manning","year":"2017","unstructured":"Manning BD, Toker A. AKT\/PKB signaling: navigating the network. Cell. 2017;169:381\u2013405. https:\/\/doi.org\/10.1016\/j.cell.2017.04.001.","journal-title":"Cell"},{"issue":"5","key":"3294_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051179","volume":"12","author":"H Jung","year":"2020","unstructured":"Jung H, Yoon SR, Lim J, Cho HJ, Lee HG. Dysregulation of Rho GTPases in human cancers. Cancers. 2020;12(5):1179. https:\/\/doi.org\/10.3390\/cancers12051179.","journal-title":"Cancers"},{"key":"3294_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02234-x","volume":"21","author":"Y Lou","year":"2021","unstructured":"Lou Y, Jiang Y, Liang Z, Liu B, Li T, Zhang D. Role of RhoC in cancer cell migration. Cancer Cell Int. 2021;21:527. https:\/\/doi.org\/10.1186\/s12935-021-02234-x.","journal-title":"Cancer Cell Int"},{"key":"3294_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-63","volume":"13","author":"C Gest","year":"2013","unstructured":"Gest C, Joimel U, Huang L, Pritchard L-L, Petit A, Dulong C, et al. Rac3 induces a molecular pathway triggering breast cancer cell aggressiveness: differences in MDA-MB-231 and MCF-7 breast cancer cell lines. BMC Cancer. 2013;13:63. https:\/\/doi.org\/10.1186\/1471-2407-13-63.","journal-title":"BMC Cancer"},{"key":"3294_CR67","doi-asserted-by":"publisher","first-page":"759","DOI":"10.2741\/2718","volume":"13","author":"Y Tang","year":"2008","unstructured":"Tang Y, Olufemi L, Wang MT, Nie D. Role of rho GTPases in breast cancer. Front Biosci. 2008;13:759\u201376. https:\/\/doi.org\/10.2741\/2718.","journal-title":"Front Biosci"},{"issue":"17","key":"3294_CR68","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.7150\/ijms.43101","volume":"17","author":"M Privat","year":"2020","unstructured":"Privat M, Cavard A, Zekri Y, Ponelle-Chachuat F, Molnar I, Sonnier N, et al. A high expression ratio of RhoA\/RhoB is associated with the migratory and invasive properties of basal-like breast tumors. Int J Med Sci. 2020;17(17):2799\u2013808.","journal-title":"Int J Med Sci"},{"issue":"5","key":"3294_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051292","volume":"12","author":"P Zubor","year":"2020","unstructured":"Zubor P, Dankova Z, Kolkova Z, Holubekova V, Brany D, Mersakova S, et al. Rho GTPases in Gynecologic Cancers: in-depth analysis toward the paradigm change from reactive to predictive, preventive, and personalized medical approach benefiting the patient and healthcare. Cancers. 2020;12(5):1292. https:\/\/doi.org\/10.3390\/cancers12051292.","journal-title":"Cancers"},{"issue":"7","key":"3294_CR70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040979","volume":"7","author":"DT Rosenthal","year":"2012","unstructured":"Rosenthal DT, Zhang J, Bao L, Zhu L, Wu Z, Toy K, et al. RhoC impacts the metastatic potential and abundance of breast cancer stem cells. PLoS One. 2012;7(7):e40979. https:\/\/doi.org\/10.1371\/journal.pone.0040979.","journal-title":"PLoS One"},{"issue":"6","key":"3294_CR71","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1200\/jco.2003.02.063","volume":"21","author":"IC Henderson","year":"2003","unstructured":"Henderson IC, Berry DA, Demetri GD, Cirrincione C, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21(6):976. https:\/\/doi.org\/10.1200\/jco.2003.02.063.","journal-title":"J Clin Oncol"},{"key":"3294_CR72","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2024.180","author":"\u00c9 Larose","year":"2025","unstructured":"Larose \u00c9, Hua X, Yu S, Pillai AK, Yi Z, Yu H. Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing [Review of Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing]. Cancer Drug Resist. 2025. https:\/\/doi.org\/10.20517\/cdr.2024.180.","journal-title":"Cancer Drug Resist"},{"issue":"16","key":"3294_CR73","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1200\/jco.2005.10.517","volume":"23","author":"EP Mamounas","year":"2005","unstructured":"Mamounas EP, Bryant J, Lembersky BC, Fehrenbacher L, Sedlacek S, Fisher B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005;23(16):3686. https:\/\/doi.org\/10.1200\/jco.2005.10.517.","journal-title":"J Clin Oncol"},{"issue":"26","key":"3294_CR74","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.2174\/092986732126140804160443","volume":"21","author":"C Chen","year":"2014","unstructured":"Chen C, Chen J, Zhao K. Editorial (thematic issue: signalling pathways in anti-cancer drug resistance). Curr Med Chem. 2014;21(26):3007. https:\/\/doi.org\/10.2174\/092986732126140804160443.","journal-title":"Curr Med Chem"},{"issue":"6","key":"3294_CR75","doi-asserted-by":"publisher","DOI":"10.1053\/ejso.2002.1303","volume":"28","author":"A Liem","year":"2002","unstructured":"Liem A, Chamberlain M, Wolf CR, Thompson AM. The role of signal transduction in cancer treatment and drug resistance [Review of The role of signal transduction in cancer treatment and drug resistance]. Eur J Surg Oncol. 2002;28(6):679. https:\/\/doi.org\/10.1053\/ejso.2002.1303.","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"3294_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25021063","volume":"25","author":"O Menyh\u00e1rt","year":"2024","unstructured":"Menyh\u00e1rt O, Fekete JT, Gy\u0151rffy B. Resistance to combined anthracycline\u2013taxane chemotherapy is associated with altered metabolism and inflammation in breast carcinomas. Int J Mol Sci. 2024;25(2):1063. https:\/\/doi.org\/10.3390\/ijms25021063.","journal-title":"Int J Mol Sci"},{"key":"3294_CR77","doi-asserted-by":"publisher","unstructured":"Liu R, Chen Y, Liu G, Li C, Song Y, Cao Z, Li W, Hu J, L\u00fc C, Liu Y. PI3K\/AKT pathway as a key link modulates the multidrug resistance of cancers [Review of PI3K\/AKT pathway as a key link modulates the multidrug resistance of cancers]. Cell Death and Disease.\u00a02020;11(9). Springer Nature. https:\/\/doi.org\/10.1038\/s41419-020-02998-6","DOI":"10.1038\/s41419-020-02998-6"},{"key":"3294_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112954","volume":"210","author":"T Liu","year":"2020","unstructured":"Liu T, Song S, Wang X, Hao J. Small-molecule inhibitors of breast cancer-related targets: Potential therapeutic agents for breast cancer [Review of Small-molecule inhibitors of breast cancer-related targets: Potential therapeutic agents for breast cancer]. Eur J Med Chem. 2020;210:112954. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112954.","journal-title":"Eur J Med Chem"},{"issue":"14","key":"3294_CR79","doi-asserted-by":"publisher","first-page":"10141","DOI":"10.1074\/jbc.275.14.10141","volume":"275","author":"K Abe","year":"2000","unstructured":"Abe K, Rossman K, Liu B, Ritola K, Chiang D, Campbell S, Burridge K, Der C. Vav2 Is an Activator of Cdc42, Rac1, and RhoA. J Biol Chem. 2000;275(14):10141\u20139. https:\/\/doi.org\/10.1074\/jbc.275.14.10141.","journal-title":"J Biol Chem"},{"issue":"4","key":"3294_CR80","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00018-011-0760-0","volume":"69","author":"PP Lie","year":"2012","unstructured":"Lie PP, Cheng CY, Mruk DD. The biology of interleukin-1: emerging concepts in the regulation of the actin cytoskeleton and cell junction dynamics. Cell Mol Life Sci. 2012;69(4):487\u2013500. https:\/\/doi.org\/10.1007\/s00018-011-0760-0.","journal-title":"Cell Mol Life Sci"},{"issue":"19","key":"3294_CR81","doi-asserted-by":"publisher","first-page":"7160","DOI":"10.1128\/MCB.20.19.7160-7169.2000","volume":"20","author":"BP Liu","year":"2000","unstructured":"Liu BP, Burridge K. Vav2 activates Rac1, Cdc42, and RhoA downstream from growth factor receptors but not beta1 integrins. Mol Cell Biol. 2000;20(19):7160\u20139. https:\/\/doi.org\/10.1128\/MCB.20.19.7160-7169.2000.","journal-title":"Mol Cell Biol"},{"issue":"22","key":"3294_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/cells11223565","volume":"11","author":"EJ Koubek","year":"2022","unstructured":"Koubek EJ, Santy LC. Actin up: an overview of the Rac GEF Dock1\/Dock180 and its role in cytoskeleton rearrangement. Cells. 2022;11(22):3565. https:\/\/doi.org\/10.3390\/cells11223565.","journal-title":"Cells"},{"issue":"7","key":"3294_CR83","doi-asserted-by":"publisher","first-page":"6196","DOI":"10.1074\/jbc.M307261200","volume":"279","author":"T Wittmann","year":"2004","unstructured":"Wittmann T, Bokoch GM, Waterman-Storer CM. Regulation of microtubule destabilizing activity of Op18\/stathmin downstream of Rac1. J Biol Chem. 2004;279(7):6196\u2013203. https:\/\/doi.org\/10.1074\/jbc.M307261200.","journal-title":"J Biol Chem"},{"issue":"2","key":"3294_CR84","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/sj.bjc.6605489","volume":"102","author":"C Stengel","year":"2009","unstructured":"Stengel C, Newman SP, Leese MP, Potter BV, Reed MJ, Purohit A. Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents. Br J Cancer. 2009;102(2):316\u201324. https:\/\/doi.org\/10.1038\/sj.bjc.6605489.","journal-title":"Br J Cancer"},{"issue":"21","key":"3294_CR85","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215386","volume":"13","author":"M Saliani","year":"2021","unstructured":"Saliani M, Mirzaiebadizi A, Mosaddeghzadeh N, Ahmadian MR. RHO GTPase-related long noncoding RNAs in human cancers. Cancers. 2021;13(21):5386. https:\/\/doi.org\/10.3390\/cancers13215386.","journal-title":"Cancers"},{"issue":"1","key":"3294_CR86","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-015-0564-5","volume":"17","author":"CC Ong","year":"2015","unstructured":"Ong CC, Gierke S, Pitt C, Sagolla M, Cheng CK, Zhou W, et al. Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents. Breast Cancer Res. 2015;17(1):59. https:\/\/doi.org\/10.1186\/s13058-015-0564-5.","journal-title":"Breast Cancer Res"},{"issue":"7","key":"3294_CR87","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.3390\/cancers13071538","volume":"13","author":"SCE Wright","year":"2021","unstructured":"Wright SCE, Vasilevski N, Serra V, Rod\u00f3n J, Eichhorn PJA. Mechanisms of resistance to PI3K inhibitors in cancer: adaptive responses, drug tolerance and cellular plasticity [Review of Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity]. Cancers. 2021;13(7):1538. https:\/\/doi.org\/10.3390\/cancers13071538.","journal-title":"Cancers"},{"key":"3294_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101510","volume":"26","author":"D Fu","year":"2022","unstructured":"Fu D, Hu Z, Xu X, Dai X, Liu Z. Key signal transduction pathways and crosstalk in cancer: biological and therapeutic opportunities. Transl Oncol. 2022;26:101510. https:\/\/doi.org\/10.1016\/j.tranon.2022.101510.","journal-title":"Transl Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03294-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03294-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03294-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T07:49:26Z","timestamp":1780300166000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03294-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":88,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["3294"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03294-7","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"3 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"183"}}